Eltrombopag label update sharpens liver safety warnings and indication-specific dosing
The updated eltrombopag tablet label, revised in June 2026, keeps the drug squarely in the hematology spotlight. Its clinical role remains centered on thrombocytopenic disorders in which inadequate platelet production or immune-mediated platelet loss places patients at bleeding risk, but the prescribing language now reads with even greater emphasis on hepatic monitoring, interaction management, and population-specific dose selection.
A boxed warning remains at the top of the label for two linked concerns: hepatic decompensation in patients with chronic hepatitis C treated alongside interferon and ribavirin, and severe hepatotoxicity. The practical consequence is immediate. Liver injury is not an abstract class warning here; it is a central feature of the prescribing framework, and the drug should be used only when the thrombocytopenia itself creates a real treatment barrier or bleeding hazard.
Liver toxicity sits at the center of prescribing decisions
The label instructs clinicians to monitor hepatic function before treatment and during therapy. In a drug that stimulates thrombopoietin signaling, liver injury matters for more than one reason. Hepatic dysfunction can complicate drug handling, alter platelet regulation, and amplify the risk of decompensation in people with chronic liver disease. In patients with chronic hepatitis C, eltrombopag is reserved for thrombocytopenia severe enough to prevent initiation of interferon-based therapy or to undermine maintenance of that regimen.
The safety language is equally firm in chronic liver disease more broadly. Portal vein thrombosis has been reported in patients with chronic liver disease receiving eltrombopag, and the label directs regular platelet monitoring. The biological concern is straightforward: pushing platelet counts too far upward in a patient already prone to altered portal circulation can tilt the balance toward thrombosis rather than hemostasis.
Three hematologic settings define the drug’s current use
Eltrombopag remains indicated for persistent or chronic immune thrombocytopenia in adults and children 1 year and older who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. The label keeps the scope narrow on purpose. It should be used only when the degree of thrombocytopenia and the clinical condition together increase bleeding risk. In other words, platelet boosting is not meant to normalize the count at all costs; it is meant to reduce clinically meaningful hemorrhagic danger.
The drug is also indicated for thrombocytopenia associated with chronic hepatitis C to allow initiation and maintenance of interferon-based therapy. A third indication covers severe aplastic anemia, both as part of first-line therapy with standard immunosuppressive treatment in adult and pediatric patients 2 years and older, and as treatment for patients who have had an insufficient response to immunosuppressive therapy. This range of uses reflects the common mechanism at the marrow level: stimulation of the thrombopoietin receptor can support platelet production when native hematopoiesis is impaired or insufficient.
One sentence captures the clinical tension in the label: the same mechanism that restores platelet counts can also create hepatic and thrombotic hazards if the response is pushed too far.
Dose selection now depends on diagnosis, age, and ancestry
The dosing instructions are highly indication-specific. For persistent or chronic ITP, the usual starting dose is 50 mg once daily in most adults and pediatric patients 6 years and older, with a 25 mg starting dose for children 1 to 5 years old. Doses should be adjusted to maintain a platelet count of at least 50 × 10^9/L, and the daily dose should not exceed 75 mg.
For chronic hepatitis C-associated thrombocytopenia, treatment starts at 25 mg once daily for all patients, with titration to the platelet target needed to begin antiviral therapy. The maximum daily dose is 100 mg. The dosing ceiling matters because the label’s central safety concern is not simply whether platelets rise, but whether they rise within a range that supports therapy without inviting thrombosis or liver toxicity.
The aplastic anemia instructions are more aggressive. In first-line severe aplastic anemia, the label recommends 2.5 mg/kg once daily in pediatric patients 2 to 5 years old, 75 mg once daily in those 6 to 11 years old, and 150 mg once daily in patients 12 years and older, given with standard immunosuppressive therapy. For refractory severe aplastic anemia, the starting dose is 50 mg once daily, with titration to keep platelet counts above 50 × 10^9/L and a maximum daily dose of 150 mg.
Dose reductions are required in patients with hepatic impairment and in some patients of East- or Southeast-Asian ancestry. The label’s emphasis on ancestry-specific dosing reflects known pharmacokinetic differences that can increase exposure and, by extension, the risk of toxicity if standard doses are used indiscriminately.
Administration rules are designed to prevent avoidable underexposure
Eltrombopag should be taken without a meal or with a meal low in calcium, defined here as 50 mg or less. It should be separated by at least 2 hours before or 4 hours after products containing polyvalent cations, including antacids, calcium-rich foods, and mineral supplements.
That instruction is not a trivial counseling point. Calcium and other polyvalent cations can bind the drug in the gut and reduce absorption, turning a carefully chosen dose into a biologically weaker one. In a medicine where success depends on reaching a narrow platelet target without overshooting, inconsistent absorption can complicate both efficacy and safety.
Myelodysplastic syndrome and common adverse effects remain part of the safety picture
The label still warns against use in myelodysplastic syndrome. Eltrombopag is not indicated for MDS, and the warning language also addresses increased risk of death and progression of MDS to acute myeloid leukemia. The concern here is not merely lack of benefit; it is the possibility of harm in a disease biology that is distinct from immune thrombocytopenia or aplastic anemia.
Across indications, the most common adverse reactions include anemia, nausea, pyrexia, increased alanine aminotransferase, cough, fatigue, headache, and diarrhea. These events do not carry the same urgency as hepatic failure or thrombosis, but they do shape tolerability and follow-up. For a chronic oral drug, persistence depends on whether patients can actually stay on therapy long enough to gain platelet support without accumulating intolerable toxicity.
Breastfeeding guidance and practical takeaways for clinicians
Women should not breastfeed during treatment. The label also confirms that there are no listed contraindications, but that should not be mistaken for a free-pass safety profile. The true limits are set by liver function, thrombotic risk, underlying marrow disease, and the patient’s ability to absorb the medication reliably.
For hematology and hepatology clinicians, the updated label reinforces a simple bedside rule: eltrombopag is a targeted platelet-support drug, not a general fix for low counts. Its use depends on matching indication, dose, and monitoring to the disease state in front of the clinician, with particular vigilance for hepatotoxicity, portal vein thrombosis, and drug-food interaction effects that can shift the balance between response and harm.